Mail

UK markets closed

NIKKEI 225
37,552.16
+113.55(+0.30%)
HANG SENG
16,828.93
+317.24(+1.92%)
CRUDE OIL
83.38
+1.48(+1.81%)
GOLD FUTURES
2,338.20
-8.20(-0.35%)
DOW
38,486.91
+246.93(+0.65%)
Bitcoin GBP
53,539.89
+322.84(+0.61%)

What is the true cost of the UK state pension?

To get a sense of the true value of the state pension, you can look at how much you would need to save to match it yourself

Mesoblast Limited (MESO)

NasdaqGS - NasdaqGS Real-time price. Currency in USD

Add to watchlist

5.97

+0.44

(+7.96%)

As of 03:24PM EDT. Market open.

Full screen

Trade prices are not sourced from all markets

Previous close	5.53
Open	5.86
Bid	5.96 x 200
Ask	6.01 x 200
Day's range	5.84 - 6.17
52-week range	1.61 - 10.24
Volume	467,619
Avg. volume	2,246,190

Market cap	681.004M
Beta (5Y monthly)	2.59
PE ratio (TTM)	N/A
EPS (TTM)	N/A
Earnings date	N/A
Forward dividend & yield	N/A (N/A)
Ex-dividend date	N/A
1y target est	N/A

All

News

Press releases

GlobeNewswire
United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)
NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that U.S. FDA has informed the company that following additional consideration the available clinical data from its Phase 3 study MSB-GVHD001 appears sufficient to support submission of the proposed Biologics License Application (BLA) for remestemcel-L for treatment of pediatric patients with steroid-refractory acute graf
GlobeNewswire
Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer
NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has received firm commitments to complete its pro-rata accelerated non-renounceable entitlement offer that was launched on 4 December, 2023 (Entitlement Offer). Together the entitlement offer and institutional placement raised gross proceeds of A$97 million, including A$36.7 million committed today on the same terms as
GlobeNewswire
United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD)
NEW YORK, March 10, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that U.S. FDA supports an accelerated approval pathway for rexlemestrocel-L, Mesoblast’s allogeneic mesenchymal precursor cell (MPC) product, in patients with end-stage ischemic heart failure with reduced ejection fraction (HFrEF) and a left ventricular assist device (LVAD). FDA provided this feedback in formal minutes to

NIKKEI 22537,552.16+113.55(+0.30%)

HANG SENG16,828.93+317.24(+1.92%)

CRUDE OIL83.38+1.48(+1.81%)

GOLD FUTURES2,338.20-8.20(-0.35%)

DOW38,486.91+246.93(+0.65%)

Bitcoin GBP53,539.89+322.84(+0.61%)

What is the true cost of the UK state pension?

Mesoblast Limited (MESO)

United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)

Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer

United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD)

NIKKEI 225
37,552.16
+113.55(+0.30%)

HANG SENG
16,828.93
+317.24(+1.92%)

CRUDE OIL
83.38
+1.48(+1.81%)

GOLD FUTURES
2,338.20
-8.20(-0.35%)

DOW
38,486.91
+246.93(+0.65%)

Bitcoin GBP
53,539.89
+322.84(+0.61%)